Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O94886
UPID:
CSCL1_HUMAN
Alternative names:
Transmembrane protein 63A
Alternative UPACC:
O94886; Q53GI7; Q5TE96; Q8N2U2
Background:
CSC1-like protein 1, also known as Transmembrane protein 63A, plays a crucial role in cellular processes by acting as an osmosensitive calcium-permeable cation channel. It is a mechanosensitive ion channel that translates mechanical stimuli into ion flow, essential for maintaining cellular homeostasis.
Therapeutic significance:
Linked to Leukodystrophy, hypomyelinating, 19, transient infantile, a disorder marked by early infantile motor delay and hypomyelination that spontaneously resolves during childhood. Understanding CSC1-like protein 1's role could unveil new therapeutic strategies for this and potentially other neurological disorders.